While Mounjaros primary approval is for type 2 diabetes, its effectiveness in weight loss is significant, positioning it as an important option in diabetes care and weight management strategies
North America: The rising prevalence of diabetes and obesity, especially in the United States, makes North America a market leader in GLP-1 analogues
Thus a 70 kg (150 lbs) person would be given around 110 g a day in hypothetical future research trials involving BPC-157 as an oral supplement
These consumers are aggressive early adopters
Asia-Pacific: The Fastest-Growing Region Asia-Pacific held a 15% share of the GLP-1 market in 2025 and is expected to grow at the fastest CAGR of 18.2% during the projection period, driven by a growing diabetic population and rising obesity prevalence
Drinking or eating less, along with nausea, vomiting, or diarrhea, can all leave you more dehydrated and dry-mouthed